Placebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral ?-endorphin concentrations in premenstrual syndrome

Basit Öğe Kaydı
dc.authoridBuhur, Ali/0000-0003-1228-0962
dc.authorwosidtaskin, omur/C-6864-2016
dc.authorwosidBuhur, Ali/GLQ-5966-2022
dc.contributor.authorTaskin, O
dc.contributor.authorGökdeniz, R
dc.contributor.authorYalcinoglu, A
dc.contributor.authorBuhur, A
dc.contributor.authorBurak, F
dc.contributor.authorAtmaca, R
dc.contributor.authorOzekici, U
dc.date.accessioned2024-08-04T20:11:58Z
dc.date.available2024-08-04T20:11:58Z
dc.date.issued1998
dc.departmentİnönü Üniversitesien_US
dc.description51st Annual Meeting of the American-Society-for-Reproductive-Medicine -- OCT 07-13, 1995 -- SEATTLE, WAen_US
dc.description.abstractCentral nervous system hormones have been linked to premenstrual syndrome (PMS) and beta-endorphin (beta-EP) is thought to be involved in the pathophysiology. We have tested the efficacy of the synthetic steroid Org OD 14 (tibolone) in the treatment of PMS, This prospective, randomized, placebo-controlled, double-blind cross-over study included 18 ovulatory women with PMS as ascertained by a visual linear analogue scale (VLAS), The women in each group received either 2.5 mg per day Org OD 14 (n = 9) or a multi-vitamin pill as placebo (n = 9) for 3 months. Treatments were then crossed over to a placebo for a further 3 months, VLAS ratings were evaluated at the end of each menstrual cycle throughout the study. Peripheral beta-EP concentrations were determined by radioimmunoassay on days 7 and 25 of each menstrual cycle. Changes in VLAS score and beta-EP concentrations from baseline were calculated and analysed by Student's paired t-test, Improvements in VLAS scores and beta-EP concentrations were evident during the second and third months of tibolone treatment. At the end of the third month, there was a significant improvement in VLAS scores of all symptom categories compared with pretreatment and placebo during treatment with tibolone (P < 0.05), Similar results were obtained in the first placebo group when switched to tibolone, beta-EP concentrations were not significantly different between the study groups at the initial cycle (15.9 +/- 3.6 versus 17.2 +/- 2.3 pg/ml), The increase in beta-EP concentration was significantly greater on day 25 of the menstrual cycle in women treated with tibolone compared with baseline and placebo group (22.5 +/- 4.4 versus 15.9 +/- 3.6 and 17.2 +/- 2.3 pg/ml respectively, P < 0.05). Our data confirm the clinical efficacy of tibolone in PMS-related symptoms, as well as its effects on serum beta-EP concentrations in patients with PMS.en_US
dc.description.sponsorshipAmer Soc Reprod Meden_US
dc.identifier.doi10.1093/humrep/13.9.2402
dc.identifier.endpage2405en_US
dc.identifier.issn0268-1161
dc.identifier.issn1460-2350
dc.identifier.issue9en_US
dc.identifier.pmid9806257en_US
dc.identifier.scopus2-s2.0-0031705732en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2402en_US
dc.identifier.urihttps://doi.org/10.1093/humrep/13.9.2402
dc.identifier.urihttps://hdl.handle.net/11616/93105
dc.identifier.volume13en_US
dc.identifier.wosWOS:000077290900018en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofHuman Reproductionen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbeta-endorphinen_US
dc.subjectpremenstrual syndromeen_US
dc.subjecttiboloneen_US
dc.subjecttherapyen_US
dc.titlePlacebo-controlled cross-over study of effects of tibolone on premenstrual symptoms and peripheral ?-endorphin concentrations in premenstrual syndromeen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu